GlassScriptPhysician profile
Changrae Kim
NPI 1083022149
$1,224.17
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $357 · 2021: $150 · 2022: $14.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $410.07 | 2019-2020 | |
| Amarin Pharma, INC. | $242.73 | 2019-2020 | |
| Stryker Corporation | $150.35 | 2021 | |
| Novo Nordisk INC | $149.35 | 2019 | |
| Gilead Sciences, INC. | $125.00 | 2020 | |
| Smith+Nephew, INC. | $59.22 | 2019-2022 | |
| Integra Lifesciences Corporation | $58.04 | 2019 | |
| Allergan, INC. | $16.60 | 2019 | |
| Wright Medical Technology, INC. | $12.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Changrae Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.